Actively Recruiting
Study of Low Muscle Mass and Chemotherapy Side Effects in Older Adults With Advanced Colorectal Cancer
Led by Wake Forest University Health Sciences · Updated on 2026-10-07
300
Participants Needed
147
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the relationship between low muscle mass myopenia at the time of diagnosis and chemotherapy side effects in older adults newly diagnosed with advanced colorectal cancer. This observational study focuses on patients receiving 5-Fluorouracil 5-FU based chemotherapy, including combinations with oxaliplatin, irinotecan, or immunotherapy. The study also investigates how genetic differences may influence the link between myopenia and chemotherapy toxicity. Participants include older adults with newly diagnosed metastatic colorectal cancer or recent metastatic recurrence who are starting or planning to start first-line immunotherapy andor 5-FU chemotherapy. The study examines chemotherapy toxicities graded 3 to 5 during the first 6 months after beginning treatment and tracks overall survival for one year. No specific treatments are administered by the study, as it observes patients undergoing standard care. During the study, participants chemotherapy side effects are monitored and recorded, along with survival outcomes. Questionnaires are used to gather patient information, and eligibility requires the ability to understand English or Spanish. The study collects data for up to one year to evaluate how muscle mass and genetics affect chemotherapy outcomes in this population.
CONDITIONS
Brief Title
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Research Team
K
Karen Craver
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here